Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel - Takeaways - MDSpire

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

  • By

  • Noopur Raje

  • Kenneth Anderson

  • Hermann Einsele

  • Yvonne Efebera

  • Francesca Gay

  • Sarah P. Hammond

  • Alexander M. Lesokhin

  • Sagar Lonial

  • Heinz Ludwig

  • Philippe Moreau

  • Krina Patel

  • Karthik Ramasamy

  • Maria-Victoria Mateos

  • August 1, 2023

  • 0 min

Share

  • 1

    Bispecific antibodies (BsAbs) are a novel immunotherapeutic class for treating multiple myeloma (MM) by activating T cells to target tumor cells.

  • 2

    Teclistamab and elranatamab are the most advanced BsAbs targeting BCMA, with both receiving accelerated approvals for relapsed/refractory MM.

  • 3

    Patients with triple-class refractory MM have a poor prognosis, with a median overall survival of only 12.4 months under current treatments.

  • 4

    Increased infection risk is associated with BsAbs due to immune impairment, with infection rates ranging from 33% to 76% in clinical trials.

  • 5

    Consensus recommendations for infection management in MM patients receiving BsAbs were developed by a panel of 13 experts based on clinical evidence.

Original Source(s)

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

  • by Noopur Raje, Kenneth Anderson, Hermann Einsele, Yvonne Efebera, Francesca Gay, Sarah P. Hammond, Alexander M. Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krina Patel, Karthik Ramasamy, Maria-Victoria Mateos

  • August 1, 2023

Related Content

Exploring the Therapeutic Promise of γδ T Cells in Blood Disorders: Bridging Immunobiology and Clinical Innovation

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

Clinical Reasoning in Practice: Implementing High-Value Care When Data Discrepancies Arise